Download - IB Final Copy
-
7/31/2019 IB Final Copy
1/37
MMS SEM-3
-
7/31/2019 IB Final Copy
2/37
RANBAXYA
Presentation on
Largest pharmaceutical company out of India
with global reach and competencies across the value chain
-
7/31/2019 IB Final Copy
3/37
CONTENTS
INTRODUCTION MISSION &VALUES
GLOBAL PRESENCE
JOURNEY
MODE OF ENTRY THE GLOBAL GENERICS ADVANTAGES
COMPETITIVE ADVANTAGES
RESEARCH & DEVELOPMENT
GLOBAL MANUFACTURING STRENGTH
DEVELOPED MARKET PRESENCE
EMERGING MARKET PRESENCE
CORPORATE SOCIAL RESPONSIBILITY
-
7/31/2019 IB Final Copy
4/37
INTRODUCTION
-
7/31/2019 IB Final Copy
5/37
Founded in 1961
Ranbaxy was started by Ranbir Singh and Gurbax Singh in
1937 as a distributor for a Japanese company Shionogi
India's largest pharmaceutical companies , Ranbaxy & Daiichi
Sankyo combined rank among the top 20 global
pharmaceutical companies
Worldwide Presence - Ground presence in 46 countries, products sold in over
125 countries
Manufacturing locations in 8 countries
-
7/31/2019 IB Final Copy
6/37
Highest R&D spender amongst Indian Pharmaceutical
companiesBusiness
International 77%
Domestic 23%
Around 14000 employees globally represented by 50
nationalities
One of the largest distribution networks that comprises over
4000 field force Project 'Viraat' - A key initiative to strengthen company's
domestic leadership position
-
7/31/2019 IB Final Copy
7/37
MISSION
&VALUES
-
7/31/2019 IB Final Copy
8/37
MISSIONEnriching lives globally, with quality and affordable
pharmaceuticals
VALUES
Achieving customer satisfaction is fundamental to our business
Provide products and services of the highest quality
Practice dignity and equity in relationships and provide
opportunities for our people to realize their full potential
Ensure profitable growth and enhance wealth of the shareholders
Foster mutually beneficial relations with all our business partners Manage our operations with high concern for safety and
environment
Be a responsible corporate citizen
-
7/31/2019 IB Final Copy
9/37
GLOBAL PRESENCE
-
7/31/2019 IB Final Copy
10/37
-
7/31/2019 IB Final Copy
11/37
-
7/31/2019 IB Final Copy
12/37
North America &
Japan
Europe
Other Emerging
Markets
BRICS
No. 1 in India
Large, reputed player inCIS; growing rapidly
No. 6 in Brazil
No. 5 in S. Africa
43/54 countries in Africa
Latam & Asia Pacific:long standing presence;good understanding;robust businesses
Pioneer entrant from
India Strong local presence
Canada: New market,growing rapidly
Well established
23/25 EU markets
No. 1 Generic player inRomania
http://images.google.com/imgres?imgurl=http://www.molsci.csiro.au/library/gifs/compass.gif&imgrefurl=http://www.molsci.csiro.au/library/compass.html&h=344&w=333&sz=5&hl=en&start=5&um=1&usg=__sF-kZKyOnm_27RqfytHy2J4-u9Q=&tbnid=bojfNRH6EAixTM:&tbnh=120&tbnw=116&prev=/images?q=compass+image&um=1&hl=en&rlz=1T4GGLG_en___IN298&sa=Nhttp://images.google.com/imgres?imgurl=http://www.molsci.csiro.au/library/gifs/compass.gif&imgrefurl=http://www.molsci.csiro.au/library/compass.html&h=344&w=333&sz=5&hl=en&start=5&um=1&usg=__sF-kZKyOnm_27RqfytHy2J4-u9Q=&tbnid=bojfNRH6EAixTM:&tbnh=120&tbnw=116&prev=/images?q=compass+image&um=1&hl=en&rlz=1T4GGLG_en___IN298&sa=N -
7/31/2019 IB Final Copy
13/37
In June 2008, Daiichi-Sankyo acquired a 34.8% stake inRanbaxy, for a value $2.4 billion
In November 2008, Daiichi-Sankyo completed the takeover of
the company from the founding Singh family in a deal worth
$4.6 billion
by acquiring a 63.92% stake in Ranbaxy
Significant and sustained operational and strategic synergies
across the globe
Combining innovator and generics capabilities, to straddle full
spectrum of pharma value chain
-
7/31/2019 IB Final Copy
14/37
HEADQUARTERS
LOCATED AT GURGAON, NEW DELHI
-
7/31/2019 IB Final Copy
15/37
JOURNEY
-
7/31/2019 IB Final Copy
16/37
-
7/31/2019 IB Final Copy
17/37
MODE OF ENTRY
-
7/31/2019 IB Final Copy
18/37
Foreign Direct Investment(FDI)
Joint Venture
Acquisition
Licensing
-
7/31/2019 IB Final Copy
19/37
STRATEGY
-
7/31/2019 IB Final Copy
20/37
Follows a geocentric approach
It is the Companys constant endeavour to provide a wide
basket of generic and innovator products, leveraging the
unique Hybrid Business Model with Daiichi Sankyo
-
7/31/2019 IB Final Copy
21/37
BUSINESS MODEL
-
7/31/2019 IB Final Copy
22/37
THE GLOBAL GENERICSADVANTAGES
-
7/31/2019 IB Final Copy
23/37
-
7/31/2019 IB Final Copy
24/37
COMPETITIVE ADVANTAGES
-
7/31/2019 IB Final Copy
25/37
-
7/31/2019 IB Final Copy
26/37
RESEARCH & DEVELOPMENT
-
7/31/2019 IB Final Copy
27/37
Dedicated Facilities for Innovative & Generics Research
More than 1200 R&D Personnel
Highest R&D spender amongst Indian Pharmaceutical
companies
NDDS based products (4 platform technologies)
NDDR - Arterolane + PQP (Anti malaria)
One program with GSK (Respiratory)
Collaboration in Clinical Development of NCE
-
7/31/2019 IB Final Copy
28/37
GLOBAL MANUFACTURINGSTRENGTH
-
7/31/2019 IB Final Copy
29/37
7 manufacturing locations worldwide
API facilities - increasing vertical integration
Creating capacities for specialty products
New facilities added in cost advantageous geographies
-
7/31/2019 IB Final Copy
30/37
USA IRELAND ROMANIA
INDIA SOUTH AFRICA MALAYSIA
NIGERIA
-
7/31/2019 IB Final Copy
31/37
DEVELOPED MARKETPRESENCE
-
7/31/2019 IB Final Copy
32/37
USA Largest generic market worldwide
Significant patent expiries through 2015
EUROPEAN UNION
Germany, UK - mature markets
France, Spain, Italy, Romania - emerging markets
Ranbaxy has presence in 23 of the 27 EU countries
JAPAN
Emerging generic market
Opportunity to develop, manufacture & supply products through
Daiichi Sankyo
-
7/31/2019 IB Final Copy
33/37
EMERGING MARKET PRESENCE
-
7/31/2019 IB Final Copy
34/37
INDIA Among India's largest pharmaceutical companies
Growing at a fast pace
ROMANIA
Ranked as the No. 1 Generics Company
Strategic for servicing EU operations
RUSSIA & UKRAINE
Strong base in acute therapies
Fast expanding into chronic and OTC segments
SOUTH AFRICA
Key market in the African continent
A stron No. 5 la er in the re ion
-
7/31/2019 IB Final Copy
35/37
Corporate social
responsibility
-
7/31/2019 IB Final Copy
36/37
-
7/31/2019 IB Final Copy
37/37